September 15, 2022, Palo Alto, California – Koji Tanabe of I Peace, Inc. and a researcher Hiroko Nobuta of the University of California, San Francisco (currently assistant professor at Rutgers University) successfully achieved the direct reprogramming: the direct and rapid transformation of Dermal fibroblasts into Oligodendrocyte precursor cells by inducing four genes into the cells. This research was jointly conducted with Prof. Wernig at Sanford University and Prof. Rowitch at UCSF. The research was published in the online edition of an academic journal “Development” on June 24th. [Read more…]
Applied StemCell Announces the Expansion of its cGMP Manufacturing Facility to Support Cell and Gene Therapy
MILPITAS, Calif. — Applied StemCell, Inc. (ASC), a leading cell and gene therapy CRO/CDMO focused on supporting the research community and biotechnology industry for their needs in developing and manufacturing cell and gene products, today announced the expansion of its Current Good Manufacturing (cGMP) facility. ASC has successfully carried out cell banking and product manufacturing projects in its current cGMP suite and is now set on building 4 additional cGMP cleanrooms, cryo-storage space, and a process development and QC/QA space. [Read more…]
Hemostemix. The Canadian Biotech that Could Change Healthcare as We Know It.
*Sponsored Content: The article is sponsored by Hemostemix Inc.
Hemostemix Inc. (“Hemostemix”) (TSX Venture:HEM; OTCQB:HMTXF) is a publicly traded clinical-stage biotech company that develops and commercializes blood-derived stem cell therapies for medical conditions lacking adequate treatment options. Importantly, it is one of the first clinical-stage biotech companies to test a stem cell therapy within an international, multi-center Phase II clinical trial for patients with critical limb ischemia (“CLI”). CLI is a severe form of peripheral artery disease (“PAD”) that is caused by reduced blood flow to the extremities. [Read more…]
Laverock Therapeutics founded to develop the next generation of programmable cell therapies
31st August 2022, Stevenage, UK — Laverock Therapeutics Ltd was founded to develop a unique gene silencing platform for the creation of programmable, allogeneic cell therapies. Having recently completed a seed funding round, the Company has opened dedicated labs in the Stevenage Bioscience Catalyst, employing six new team members on top of an experienced senior management team. [Read more…]
Steakholder Foods Initiates Cultured Pork Development Using a Porcine Cell Line with Significantly Greater Lifespan and Scalability
The new induced pluripotent porcine stem cell line (iPS) enables the company to continue diversifying its species portfolio and accelerate its market readiness for cultured pork production
- « Previous Page
- 1
- …
- 148
- 149
- 150
- 151
- 152
- …
- 340
- Next Page »